Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia.

Valentiny, C; Mitrovic, M; Pleyer, L; Steurer, M; Willenbacher, W; Stauder, R WIEN KLIN WOCHENSCHR. 2013; 125(1-2): 50-53.

Chronic Lymphocytic Leukaemia Cells with Trisomy 12 Home to the Bone Marrow in a CXCR4-Independent Manner

Hutterer, E; Ganghammer, S; Hinterseer, E; Brachtl, G; Asslaber, D; Krenn, P; Girbl, T; Berghammer, P; Geisberger, R; Egle, A; Zucchetto, A; Gattei, V; Chigaev, A; Greil, R; Hartmann, T Chronic Lymphocytic Leukaemia Cells with Trisomy 12 Home to the Bone Marrow in a CXCR4-Independent Manner. 2014; 79(6): 424-478.-Scandinavian Society for Immunology_x000D_ 42nd Annual Meeting; 11.-14.06.2014; Reykjavik.

Spliceosome Mediated RNA Trans-Splicing for Targeting Kappa(+) B-Cell Neoplasms

Weiss, L; Gruber, C; Koller, U; Pinon-Hofbauer, J; Hainzl, S; Hufnagl, C; Melchardt, T; Brachtl, G; Greil, R; Bauer, J; Egle, A BLOOD. 2014; 124(21):

Excellent response of lupus hepatitis to mycophenolate mofetil: a case report

Psenak, O; Studnicka-Benke, A; Greil, R WIEN KLIN WOCHENSCHR. 2014; 126:

Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes

Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstocker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R BLOOD. 2014; 124(21):

Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry

Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstocker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R BLOOD. 2014; 124(21):

CXCL12 Enhances CLL Cell and T-Cell Migration in a Dynamic Circulating Model of CLL That Can be Abrogated By the CXCR4 Antagonist ONO-7161

Walsby, EJ; Brennan, P; Pratt, G; Hartmann, TN; Yoshizawa, T; Fegan, C; Pepper, C BLOOD. 2014; 124(21):

The Transcription Factor IRF4 Is Crucial for CLL Progression and Regulates Survival and Proliferation in a Microenvironment Related Manner

Asslaber, D; Hofbauer, JP; Zaborsky, N; Flenady, S; Hartmann, TN; Greil, R; Egle, A BLOOD. 2014; 124(21):

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study

Rawstron, A; Fazi, C; Villamor, N; Delgado, J; Letestu, R; Cymbalista, F; Palacio, C; Bosch, F; De Tute, RM; Liptrot, S; OxxxBrien, D; Spacek, M; Dobber, J; Kater, AP; Gambell, PC; Westerman, DA; Soosapilla, A; Mulligan, SP; Lozanski, G; Lin, K; Pettitt, AR; Brachtl, G; Egle, A; Williamson, DW; Sanders, CM; Robins, H; Boysen, J; Shanafelt, TD; Hanson, CA; Jorgensen, JL; Wierda, WG; Yuan, C; Stetler-Stevenson, M; Rassenti, L; Broome, HE; Kipps, TJ; Hauwel, M; Marinov, I; Craig, FE; Josep, N; Moreno, C; Stehlikova, O; Doubek, M; Pospisilova, S; Kreuzer, KA; Hallek, M; Hillmen, P; Montserrat, E; Ghia, P BLOOD. 2014; 124(21):

Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study

Gisslinger, H; Buxhofer-Ausch, V; Thaler, J; Schloegl, E; Gastl, GA; Wolf, D; Kralovics, R; Gisslinger, B; Strecker, K; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Zoerer, M; Kadlecova, P; Zagrijtschuk, O; Klade, C; Greil, R BLOOD. 2014; 124(21):